Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. was founded in 1998 and is based in New York, New York. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Its products under development include Zerenex, an oral iron-based compound is in Phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease in the United States and Japan; and KRX-0401, an oral anti-cancer agent in Phase II clinical development that modulates Akt, and various other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Keryx Biopharmaceuticals has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products.

Contact Details

Office Address

Keryx Biopharmaceuticals, Inc.
750 Lexington Ave. - 20th Floor
New York, NY, USA 10022
Phone: (212) 531-5965
Fax: (212) 531-5961

Executives

Principal Financial Officer, Principal Accounting Officer, Sec. and Treasurer

Mr. James F. Oliviero

Chief Exec. Officer

Mr. Ron Bentsur

Business Reviews for Keryx Biopharmaceuticals, Inc.

Related Companies